FDA Approves Outlook's Lytenava for Wet AMD

The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt.

Learn more about your ad choices. Visit megaphone.fm/adchoices